home / stock / btx / btx news

BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 11/09/21

Stock Information
Company Name: Brooklyn ImmunoTherapeutics Inc.
Stock Symbol: BTX
Market: NYSE
Website: biotimeinc.com
Menu
BTX BTX Quote BTX Short BTX News BTX Articles BTX Message Board
Get BTX Alerts

News, Short Squeeze, Breakout and More Instantly...
BTX - Brooklyn Immunotherapeutics EPS misses by $1.62

Brooklyn Immunotherapeutics (NASDAQ:BTX): Q3 GAAP EPS of -$1.70 misses by $1.62. Cash of $24.4M. Press Release For further details see: Brooklyn Immunotherapeutics EPS misses by $1.62

BTX - Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and...

BTX - Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood diso...

BTX - Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, a...
BTX - Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood dis...

BTX - Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...

BTX - Shares of Brooklyn ImmunoTherapeutics Inc. Under Pressure, Down 17.5%

Brooklyn ImmunoTherapeutics Inc. (AMX:BTX) is one of today's biggest movers, down 17.5% to $9.86. Over the past year, Brooklyn ImmunoTherapeutics Inc. has traded in a range of $3.10 to $80.67 and is now at $9.86, 218% above that low. Receive IBN Spotlights - "Bite Size" Small, Mid and ...
BTX - Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts PR Newswire CAMBRIDGE, Mass. , Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambrid...

BTX - Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET

BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood d...

BTX - Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...
Previous 10 Next 10